Chronic Lymphocytic Leukemia – VJRegenMed

Safety and efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL

Anya Kerkache — Thu, 09 Mar 2023 11:31:47 +0000

Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, comments on the results of two studies evaluating the LV20.19 CAR-T product in patients with Richter’s transformation and in patients with heavily pretreated mantle cell lymphoma (MCL; NCT04186520). Out of the six patients with Richter’s transformation who were evaluated, four achieved a durable remission and the overall response rate (ORR) was 100%. Patients presented a unique toxicity profile, with a high incidence of hemophagocytic lymphohistiocytosis (HLH)-like toxicity. In MCL, eight of the 14 patients in the study met the primary endpoint, and the ORR at day 90 was 100%. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

CAR-T therapy in acute and chronic leukemias: current applications and future outlooks

Anya Kerkache — Wed, 08 Mar 2023 10:35:19 +0000

John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, shares some insights into clinical indications for CAR-T therapy in acute and chronic leukemias, highlighting recent updates and challenges in this space. Prof. Gribben first discusses the role of CAR-T therapy in acute lymphoblastic leukemia (ALL), drawing focus on the two approved products in this malignancy. Prof. Gribben then goes on to explain mechanisms of resistance to CAR-T therapy in ALL, and ongoing research in this space. Following this, Prof. Gribben discusses updates and challenges with the use of CAR-T therapy in T-cell malignancies and acute myeloid leukemia (AML), and concludes by highlighting challenges with developing efficacious CAR-T products for chronic lymphocytic leukemia (CLL), which may be overcome by combining CAR-T cells with Bruton’s tyrosine kinase (BTK) inhibitors. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Results from the first-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL

Anya Kerkache — Thu, 26 Jan 2023 12:11:27 +0000

Jakub Svoboda, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, describes the mechanism of action of huCART19-IL18, a 4th generation autologous CAR T-cell product, and outlines findings from a first-in-human trial investigating the efficacy of huCART19-IL18 in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (NHL) or chronic lymphocytic leukemia (CLL) (NCT04684563). Results from this study so far have been encouraging, with no unexpected toxicities being recorded and some patients already achieving complete response. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies

Marta Palhas — Fri, 26 Feb 2021 14:08:26 +0000

CD19 CAR T-cells are transforming the treatment of relapsed or refractory (R/R) B-cell malignancies. However, complete responses are not seen in all patients, and in a significant proportion, these responses are not durable. Jordan Gauthier, MD, MSc, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses second infusions of CD19 CAR T-cells (CART2) as a possible approach to improve outcomes in patients with R/R B-cell malignancies. An analysis of the outcomes after CART2 in patients with R/R acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia treated on a Phase I/II clinical trial of CD19 CAR T-cells of defined composition showed that CART2 was feasible and safe in most patients. Additionally, two modifiable pre-treatment factors independently associated with better outcomes after CART2 were identified. This interview took place during the 3rd European CAR T-cell Meeting.

CART19-BE-01: ARI-0001 in CD19+ malignancies

admin_vjr_user — Tue, 03 Nov 2020 17:40:00 +0000

Valentín Ortiz-Maldonado, MD, of the Hospital Clinic, Barcelona, Spain, discusses the initial results of the CART19-BE-01 (NCT03144583), a Phase I multicenter study evaluating ARI-0001, a CD19 targeting chimeric antigen receptor T-cell, in patients with CD19+ relapsed/refractory hematological malignancies. The primary and secondary endpoints of safety and efficacy were met, with an overall survival of 68.6% at one year. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Anti-CD19 CAR T-cells for adults

admin_vjr_user — Thu, 08 Oct 2020 14:08:15 +0000

David L. Porter, MD, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, outlines the use of CD-19 CAR T-cells for adults with lymphoma and leukemia, specifically discussing the sustained remissions seen in patients treated with tisagenlecleucel and axicabtagene ciloleucel. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Long-term outcomes of anti-CD19 CAR-T in R/R CLL

admin_vjr_user — Thu, 08 Oct 2020 14:08:15 +0000

David L. Porter, MD, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, explores the long-term outcomes from a randomized dose optimization study of CAR-modified T-cells in relapsed/refractory (R/R) chronic lymphoyctic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).